Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)

DEVICE12 trials

Sponsors

Alpha Tau Medical LTD.

Conditions

Locally Advanced Pancreatic CancerLocally Recurrent Prostate CancerLung CancerMetastatic Pancreatic CancerMucosal Neoplasm of Oral CavityPancreatic AdenocarcinomaPancreatic CancerProstate Adenocarcinoma

Unknown Phase

Alpha Radiation Emitters Device for the Treatment of Squamous Cell Carcinoma (DaRT)

CompletedNCT03353077

Alpha Tau Medical LTD.Skin Squamous Cell Carcinoma

Start: 2017-11-21End: 2019-07-14Updated: 2021-03-10

Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia (DaRT)

Active, not recruitingNCT03737734

Alpha Tau Medical LTD.Mucosal Neoplasm of Oral Cavity, Skin Cancer, Soft Tissue Neoplasm

Start: 2018-12-31End: 2026-12-01Target: 30Updated: 2026-04-06

Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia.

RecruitingNCT03889899

Alpha Tau Medical LTD.Mucosal Neoplasm of Oral Cavity, Skin Cancer, Soft Tissue Neoplasm

Start: 2020-10-21End: 2026-09-30Target: 30Updated: 2025-12-02

Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer

Active, not recruitingNCT04002479

Alpha Tau Medical LTD.Metastatic Pancreatic Cancer, Pancreatic Adenocarcinoma, Pancreatic Cancer +1

Start: 2020-10-20End: 2026-10-31Target: 37Updated: 2025-12-02

Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia

RecruitingNCT04534127

Alpha Tau Medical LTD.Mucosal Neoplasm of Oral Cavity, Skin Cancer, Soft Tissue Neoplasm

Start: 2020-12-22End: 2027-07-01Target: 56Updated: 2026-06-16

Retreatment With Intratumoral Diffusing Alpha Radiation Emitters

CompletedNCT04540588

Alpha Tau Medical LTD.Mucosal Neoplasm of Oral Cavity, Skin Cancer, Soft Tissue Neoplasm

Start: 2020-12-22End: 2025-12-01Updated: 2025-12-02

Neoadjuvant Interstitial Brachytherapy Using Diffusing Alpha Emitters Radiation Therapy in Men With Prostate Cancer

CompletedNCT04543903

Alpha Tau Medical LTD.Prostate Adenocarcinoma

Start: 2022-05-16End: 2025-10-01Updated: 2025-12-02

Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Lung Cancer

RecruitingNCT05632913

Alpha Tau Medical LTD.Lung Cancer, Recurrent Lung Cancer

Start: 2023-07-01End: 2027-02-01Target: 10Updated: 2026-06-16

Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer (Feasibility and Safety)

RecruitingNCT05657743

Alpha Tau Medical LTD.Metastatic Pancreatic Cancer, Pancreatic Adenocarcinoma, Pancreatic Cancer +1

Start: 2023-08-16End: 2027-11-01Target: 15Updated: 2026-06-16

Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer

RecruitingNCT06698458

Alpha Tau Medical LTD.Metastatic Pancreatic Cancer, Pancreatic Adenocarcinoma, Pancreatic Cancer

Start: 2025-06-17End: 2026-12-01Target: 50Updated: 2026-08-27

Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Advanced Pancreatic Cancer

RecruitingNCT06755359

Alpha Tau Medical LTD.Locally Advanced Pancreatic Cancer, Pancreatic Cancer

Start: 2026-03-01End: 2027-06-01Target: 40Updated: 2026-06-24

Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Recurrent Prostate Cancer

Not yet recruitingNCT07290998

Alpha Tau Medical LTD.Locally Recurrent Prostate Cancer, Prostate Cancer, Recurrent Prostate Cancer

Start: 2026-05-01End: 2029-05-01Target: 12Updated: 2026-04-06

Related Papers

Combined safety and efficacy results from three clinical studies evaluating alpha radiotherapy for advanced pancreatic cancer.

Journal of Clinical Oncology2026-05-27

Feasibility, safety and efficacy of endoscopic ultrasound-guided alpha radiotherapy for advanced pancreatic cancer: A pilot study.

Journal of Clinical Oncology2026-01-10

Inflammatory and immune marker dynamics following intratumoral alpha dart for pancreatic cancer.

Journal of Clinical Oncology2026-01-10

Interim analysis of feasibility, safety, and tumor control in two first-in-human trials of a novel alpha-emitting radionuclide for pancreatic adenocarcinoma.

Journal of Clinical Oncology2025-01-27

Extended Follow-Up Outcomes from Pooled Prospective Studies Evaluating Efficacy of Interstitial Alpha Radionuclide Treatment for Skin and Head and Neck Cancers

Cancers2024-06-2410 citations

Initial safety and tumor control results from a phase I prospective trial evaluating a novel alpha-emitting radionuclide for the treatment of locally advanced recurrent squamous cell carcinomas of the skin and head and neck.

Journal of Clinical Oncology2020-05-201 citations